Ajai Chari, MD
Minnema MC et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1. ASCO 2022;Abstract 8015.
Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract
Rodríguez-Otero P et al. A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). ASCO 2022;Abstract 8032.
Trudel S et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study. ASH 2021;Abstract 157.
Ian W Flinn, MD, PhD
Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629-39. Abstract
Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract
Neelapu SS et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial. Nat Med 2022;28(4):735-42. Abstract
Wang M et al. Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2. ASCO 2022;Abstract 7518.
Nikhil C Munshi, MD
Agha ME et al. CARTITUDE-2 Cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. EHA 2022;Abstract S185.
Anderson LD et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. ASCO 2021;Abstract 8016.
Hillengaas J et al. Ciltacabtagene autoleucel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 biological correlative analyses and updated clinical data. EHA 2022;Abstract P959.
Usmani SZ et al. Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. ASCO 2022;Abstract 8028.
Laurie H Sehn, MD, MPH
Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract
Dickinson M et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. ASCO 2022;Abstract 7500.
Morschhauser F et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH 2021;Abstract 128.
Phillips T et al. Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL), most of whom had failed prior Bruton's tyrosine kinase inhibitor (BTKi) therapy. ASH 2021;Abstract 130.
Thieblemont C et al. Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: A phase 2 study. EHA 2022;Abstract LB2364.